Placeholder

LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research

STIMIT

STIMIT is disrupting how, when, and where cancer immunotherapy is administered in order to dramatically improve patient response rates and outcomes. Specifically, STIMIT has developed a platform technology to enable extended localized release of cancer immunotherapy in the context of surgical tumor resection, which is the standard-of-care for most patients with solid tumors.

  • Michael Goldberg, PhD Founder & CEO